IRIS
AGHEMO, Alessio Michele Goffredo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.368
AS - Asia 8.339
EU - Europa 2.292
SA - Sud America 1.480
AF - Africa 412
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 8
Totale 25.918
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.082
SG - Singapore 5.293
CN - Cina 1.257
BR - Brasile 1.223
VN - Vietnam 783
FI - Finlandia 445
IE - Irlanda 324
IT - Italia 291
NG - Nigeria 272
HK - Hong Kong 264
DE - Germania 262
FR - Francia 191
GB - Regno Unito 181
CA - Canada 170
IN - India 162
NL - Olanda 141
SE - Svezia 109
AR - Argentina 106
RU - Federazione Russa 83
BD - Bangladesh 72
TR - Turchia 72
MX - Messico 62
IQ - Iraq 55
IL - Israele 49
BE - Belgio 45
ID - Indonesia 45
UA - Ucraina 39
JP - Giappone 36
EC - Ecuador 35
PK - Pakistan 35
CO - Colombia 31
EG - Egitto 31
PL - Polonia 31
ES - Italia 30
PH - Filippine 30
ZA - Sudafrica 30
VE - Venezuela 26
KE - Kenya 21
MK - Macedonia 20
IR - Iran 19
JO - Giordania 19
UZ - Uzbekistan 19
CL - Cile 17
JM - Giamaica 17
NP - Nepal 16
PY - Paraguay 16
AU - Australia 15
MA - Marocco 15
DZ - Algeria 14
SA - Arabia Saudita 14
CZ - Repubblica Ceca 12
MY - Malesia 12
PE - Perù 11
AE - Emirati Arabi Uniti 10
AL - Albania 10
AZ - Azerbaigian 10
KR - Corea 10
RO - Romania 10
AT - Austria 8
CH - Svizzera 8
KZ - Kazakistan 8
LT - Lituania 8
TN - Tunisia 8
UY - Uruguay 8
ET - Etiopia 7
GR - Grecia 7
OM - Oman 7
A2 - ???statistics.table.value.countryCode.A2??? 6
DO - Repubblica Dominicana 6
LB - Libano 6
PA - Panama 6
RS - Serbia 6
BG - Bulgaria 5
CR - Costa Rica 5
HN - Honduras 5
TW - Taiwan 5
LV - Lettonia 4
MD - Moldavia 4
NI - Nicaragua 4
SY - Repubblica araba siriana 4
TT - Trinidad e Tobago 4
BO - Bolivia 3
HU - Ungheria 3
KW - Kuwait 3
MN - Mongolia 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
TH - Thailandia 3
AM - Armenia 2
BB - Barbados 2
BS - Bahamas 2
BW - Botswana 2
EE - Estonia 2
GY - Guiana 2
KG - Kirghizistan 2
LK - Sri Lanka 2
LY - Libia 2
PT - Portogallo 2
SN - Senegal 2
Totale 25.885
Salva come PNG Salva come JPEG
Città #
Singapore 2.509
Chandler 1.920
Wilmington 1.648
Ashburn 906
The Dalles 729
San Mateo 689
San Jose 580
Dallas 562
Ann Arbor 530
Shanghai 524
Helsinki 441
Boardman 379
New York 376
Beijing 324
Dublin 322
Leawood 310
Lawrence 288
Princeton 288
Benin City 271
Ho Chi Minh City 257
Hong Kong 241
Hanoi 220
Paris 160
Woodbridge 136
Santa Clara 133
Fairfield 132
Amsterdam 115
São Paulo 110
Los Angeles 106
Toronto 99
Milan 98
London 78
Seattle 75
Council Bluffs 62
Columbus 56
San Diego 52
Orem 47
Brussels 43
Da Nang 42
Rio de Janeiro 42
Kocaeli 39
Falkenstein 38
Norwalk 33
Phoenix 33
Buffalo 31
Moscow 29
Tokyo 29
Falls Church 27
Haiphong 27
Pune 27
Curitiba 25
Belo Horizonte 24
Brooklyn 24
Chennai 24
Houston 24
Warsaw 24
Frankfurt am Main 23
Manchester 23
Mexico City 22
Baghdad 21
Rome 21
Naples 20
Porto Alegre 20
San Francisco 20
Brasília 18
Montreal 18
Nairobi 18
Boston 17
Chicago 17
Stockholm 17
Atlanta 16
Hải Dương 16
Amman 15
Cambridge 15
Campinas 15
Charlotte 15
Monmouth Junction 15
Assago 14
Johannesburg 14
Munich 14
Salvador 14
Tashkent 14
Dhaka 13
Fortaleza 13
Mumbai 13
Buenos Aires 12
Des Moines 12
Poplar 12
Redwood City 12
Reston 12
Asyut 11
Biên Hòa 11
Denver 11
Erbil 11
Las Vegas 11
Ninh Bình 11
Recife 11
Redmond 11
São José dos Campos 11
Andover 10
Totale 17.018
Salva come PNG Salva come JPEG
Nome #
Outcome of Sars-COV-2-related thyrotoxicosis in survivors of Covid-19: a prospective study 211
BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection? 161
Lack of Correlation Between Serum Anti-HBcore Detectability and Hepatocellular Carcinoma in Patients With HCV-Related Cirrhosis 157
12 weeks ombitasvir/paritaprevir-ritonavir plus ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis 152
A 13-day, interferon-free regimen for chronic hepatitis C genotype 1 patients: between fear and hope. 146
A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis 136
Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era 135
All That Glitters is Not Gold in Vedolizumab Therapy for Patients With Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis 134
Genomewide Association Study of Severe Covid-19 with Respiratory Failure 132
Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C 130
A 'Multiomic' Approach of Saliva Metabolomics, Microbiota, and Serum Biomarkers to Assess the Need of Hospitalization in Coronavirus Disease 2019 129
Quantification of Core Antigen Monitors Efficacy of Direct-acting Antiviral Agents in Patients With Chronic Hepatitis C Virus Infection 129
Allelic inhibition of displacement activity: A simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms 126
Acute tubular necrosis following interferon-based therapy for hepatitis C : case study with literature review 123
Deciding on interferon-free treatment for chronic hepatitis C : Updating liver stiffness cut-off values to maximize benefit 123
A rapid point-of-care test for the diagnosis of HCV infection: tipping the balance to screening extension beyond high risk populations? 118
Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials 115
Age Might Confound the Impact of the Transmembrane 6 Superfamily Member 2 E167K Polymorphism on Hepatic Fibrosis in Hepatitis C Virus-Infected Patients REPLY 112
Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response 112
Pegylated IFN-alpha 2a and ribavirin in the treatment of hepatitis C 111
Optimizing treatment with pegylated interferon-ribavirin of genotype 3 chronic hepatitis C : more questions than answers 110
Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population 109
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naive patients with genotype 1 chronic hepatitis C 109
Sofosbuvir for the treatment of chronic hepatitis C : between current evidence and future perspectives 107
Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis 107
Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: Effects on blood pressure control and mortality 107
Mapping the human genetic architecture of COVID-19 107
Acute allograft rejection following interferon therapy for hepatitis C in recipients who have returned to dialysis after kidney transplant failure: Case study 106
Daclatasvir for the treatment of chronic hepatitis C 106
Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside 105
Real life experiences in HCV management in 2018 105
From current status to optimization of HCV treatment: Recommendations from an expert panel 104
A Review of the Treatment of Chronic Hepatitis C Virus Infection in Cirrhosis 103
Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients 103
Clinical Outcomes in the Second versus First Pandemic Wave in Italy: Impact of Hospital Changes and Reorganization 103
Daclatasvir : a team player rather than a prima donna in the treatment of hepatitis C 102
Impaired response to interferon-alpha 2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection 102
EASL Recommendations on Treatment of Hepatitis C 2014 102
Peginterferon maintenance therapy in patients with advanced hepatitis C to prevent hepatocellular carcinoma: The plot thickens 101
Assessing long-term treatment efficacy in chronic hepatitis B and C : Between evidence and common sense 101
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma 101
DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection 101
Prevalence and clinical significance of intrahepatic cholangiocellular carcinoma with radiological enhancement pattern mimicking hepatocellular carcinoma 101
Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19 101
Anemia during peginterferon-ribavirin therapy results from both increased suppression of erythroid differentiation and haemolysis 100
Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management 99
Ribavirin impairs salivary gland function in hepatitis C patients during combination treatment with pegylated interferon alfa-2a 98
Interferon in the treatment of chronic hepatitis C: a drug caught between past and future 98
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 98
TACE with drug-eluting beads is effective for the maintenance of the milan-in status in patients with a small hepatocellular carcinoma 97
Lack of rapid virological response. predicts interferon-alpha 2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study 97
COVID-19 Digestive System Involvement and Clinical Outcomes in a Large Academic Hospital in Milan, Italy 97
A risk score based on baseline risk factors for predicting mortality in COVID-19 patients 97
The quest for safe and effective treatments of chronic hepatitis C in patients with kidney impairment 96
HCV genotype 3: An independent predictor of fibrosis progression in chronic hepatitis C 95
The role of hepatic venous pressure gradient in hepatitis C virus compensated cirrhosis 94
COINCIDENCE OF CALCITONIN-GENE-RELATED PEPTIDE IMMUNOREACTIVITY AND TERMINAL FIELDS OF EFFERENTS FROM THE CARDIOVASCULAR PORTION OF THE FASTIGIAL NUCLEUS - PRELIMINARY-REPORT 94
Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C 94
Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection 94
High levels of factor VIII and risk of extra-hepatic portal vein obstruction 94
High mortality in COVID-19 patients with mild respiratory disease 94
Hepatitis C virus post-exposure prophylaxis: A reasonable option in the era of pangenotypic direct-acting antivirals? 93
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 93
OSMOREGULATION OF VASOPRESSIN DURING ACUTE LOWERING OF ARTERIAL-PRESSURE BY CLONIDINE IN MODERATE HYPERTENSION 93
Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C 93
Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis? 93
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure 93
The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent 92
The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies 92
Interferon-ribavirin therapy induces serum antibodies determining 'rods and rings' pattern in hepatitis C patients 92
Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: The importance of tumor cell differentiation 90
The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia 90
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65years with HCV genotype 1 cirrhosis 90
Recommendations for the management of hepatitis C virus infection among people who inject drugs 90
Safety of vedolizumab in liver transplant recipients: A systematic review 90
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel 89
Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection 89
REGULATION OF VASOPRESSIN SECRETION AFTER ADMINISTRATION OF SODIUM-NITROPRUSSIDE IN HYPERTENSIVES 89
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission 89
An individualized algorithm to predict mortality in COVID-19 pneumonia: a machine learning based study 88
Individualized hepatocellular carcinoma risk : the challenges for designing successful chemoprevention strategies 88
Sofosbuvir Treatment in the Pre and Post Liver Transplantation Phase: The Sooner, the Better 88
Chemokine Receptor 5 Has No Major Role in the Severity of Hepatitis C Virus-Related Liver Damage 88
Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection 88
No clinical impact of HCV RNA determination at the end of treatment in patients receiving directly acting antivirals 87
Serological tests do not predict residual fibrosis in hepatitis C cirrhotics with a sustained virological response to interferon 87
Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF) 87
Critical Care Outreach Team During COVID-19: Ventilatory Support in the Ward and Outcomes 87
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3‐infected patients within the Italian network VIRONET‐C 87
Will the benefits of treatment for chronic hepatitis C be retained in the interferon-free era? 86
Tumor-Infiltrating Lymphocytes and Macrophages in Intrahepatic Cholangiocellular Carcinoma. Impact on Prognosis after Complete Surgery 86
Are We Ready to Discontinue Hepatitis B Immunoglobulins to Prevent Hepatitis B and D Recurrence in Liver Transplant Recipients? 86
New horizons in hepatitis C antiviral therapy with direct-acting antivirals 85
Limited Utility of ITPA Deficiency to Predict Early Anemia in HCV Patients with Advanced Fibrosis Receiving Telaprevir 85
Contribution of beta-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: Role of severity of liver disease 85
High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study 85
De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis c (case study and literature review) 85
Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature 85
Chronic hepatitis C: standard of care and perspective 84
Directly acting antivirals for the treatment of chronic hepatitis C: Unresolved topics from registration trials 84
Totale 10.282
Salva come PNG Salva come JPEG
Categoria #
all - tutte 168.916
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 168.916
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021371 0 0 0 0 0 0 0 0 0 0 0 371
2021/20221.691 79 18 59 359 20 21 77 221 121 197 405 114
2022/20234.749 675 211 459 563 430 409 7 418 877 362 273 65
2023/20242.682 184 263 549 130 103 422 149 153 38 46 250 395
2024/20253.997 118 102 51 88 96 417 286 500 551 906 459 423
2025/20269.975 1.484 628 640 876 225 408 3.173 638 560 619 351 373
Totale 26.177